A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...
Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...
PROSERA Study Overview and Baseline Characteristics ...
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...
In an era of overt sexism in the sciences, she made two major discoveries, including identifying a chemical signal in the ...
Tampa Free Press on MSN
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study
San Diego-based Gossamer Bio released long-awaited Phase 3 data today for its drug seralutinib, revealing a complex set of results that both challenged and encouraged researchers. The PROSERA study, ...
The AI model, Pleiades, accurately diagnoses early-stage neurodegenerative disease by using noninvasive blood tests to analyze the epigenome.
BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
Q4 2025 Earnings Call February 26, 2026 4:30 PM ESTCompany ParticipantsMike Brophy - Chief Financial OfficerSteve Chapman - CEO ...
Thank you. Earlier today, Seer released financial results for the quarter and year ended December 31, 2025. If you've not received this news release or if you'd like to be added to the company's ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech ...
This bioresorbable standard-size pill can be interrogated via RFID to confirm it has been taken by the patient.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results